Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Muscarinic acetylcholine receptors (mAChR) play important roles in regulating complex behaviors such as cognition, movement, and reward, making them ideally situated as potential drug targets for the treatment of several brain disorders. Recent advances in the discovery of subtype-selective allosteric modulators for mAChRs has provided an unprecedented opportunity for highly specific modulation of signaling by individual mAChR subtypes in the brain. Recently, mAChR allosteric modulators have entered clinical development for Alzheimer’s disease (AD) and schizophrenia, and have potential utility for other brain disorders. However, mAChR allosteric modulators can display a diverse array of pharmacological properties, and a more nuanced understanding of the mAChR will be necessary to best translate preclinical findings into successful clinical treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide atlas of gene expression in the adult mouse brain
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., et al. (2007) · Nature · doi:10.1038/nature05453 · Cited by 5,572
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 1×
“The M4 mAChR is abundantly expressed in the dorsal striatum, nucleus accumbens, and the nigros-triatal and mesolimbic dopaminergic pathways [25,62], circuitry that has been implicated in the positive symptoms of schizophrenia that include hallucinations, delusions, and disorganized thought [63,64], as well as motivati…”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · cited 2×
“Although AChE inhibitors such as tacrine and donepezil have demonstrated dose-dependent efficacy in improving cognition in patients with early-stage AD, they suffer from dose-limiting adverse effects attributed to generalized non-selective activation of cholinergic receptors in the CNS and periphery, thereby limiting…”
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Role of computer-aided drug design in modern drug discovery
Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0640-5 · Cited by 762 · cited 1×
“Collectively, the insights into the exact nature of orthosteric and allosteric ligand interactions provided by these crystal structures, paired with state-of-the-art in silico docking of digital compound libraries, provide the exciting potential to screen large numbers of compounds in very little time and at low cost,…”
BackgroundModes and models of forebrain cholinergic neuromodulation of cognition
Hasselmo, M. E., & Sarter, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.104 · Cited by 733
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 1×
“Therefore, these biased ligands could provide a larger therapeutic window than fentanyl, which preferentially signals through β-arrestin and produces robust respiratory depression [56,57].”
BackgroundDopamine and Cognitive Control in Prefrontal Cortex
Ott, T., & Nieder, A. (2019) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2018.12.006 · Cited by 530 · cited 6×
“Potential Cognition-Enhancing Effects of M1 PAMs The M1 mAChR is the most abundant of the five mAChR subtypes expressed in brain regions crucially involved in cognition, such as the prefrontal cortex (PFC) and hippocampus [24,25].”
BackgroundInfluentialSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286
Self-citationUhlhaas, P. J., & Singer, W. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.019 · Cited by 243
Kurimoto, E., Matsuda, S., Shimizu, Y., Sako, Y., Mandai, T., Sugimoto, T., Sakamoto, H., & Kimura, H. (2018) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243774 · Cited by 29
Cited by
Role of Cholinergic Signaling in Alzheimer’s Disease
Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F. (2022) · Molecules · doi:10.3390/molecules27061816 · Cited by 922
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Impact of GPCR Structures on Drug Discovery
Congreve, M., de Graaf, C., Swain, N. A., & Tate, C. G. (2020) · Cell · doi:10.1016/j.cell.2020.03.003 · Cited by 375
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
Bohnen, N. I., Yarnall, A. J., Weil, R. S., Moro, E., Moehle, M. S., Borghammer, P., Bedard, M.-A., & Albin, R. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00377-x · Cited by 293
A Systematic Review of Pesticide Exposure, Associated Risks, and Long-Term Human Health Impacts
Shekhar, C., Khosya, R., Thakur, K., Mahajan, D., Kumar, R., Kumar, S., & Sharma, A. K. (2024) · Toxicology Reports · doi:10.1016/j.toxrep.2024.101840 · Cited by 236
Metadata
- Authors
- Moran, S. P., Maksymetz, J., & Conn, P. J.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 40
- Issue
- 12
- Pages
- 1006-1020
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2984394901
- Cited by
- 133
- References
- 14
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.